NASDAQ:TVGN Tevogen Bio Q1 2026 Earnings Report $4.78 -0.24 (-4.78%) Closing price 07/15/2026 04:00 PM EasternExtended Trading$4.79 +0.01 (+0.13%) As of 07/15/2026 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tevogen Bio EPS ResultsActual EPS-$1.61Consensus EPS -$2.64Beat/MissBeat by +$1.03One Year Ago EPSN/ATevogen Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATevogen Bio Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsTevogen Bio's next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Tevogen Bio Earnings HeadlinesTevogen Bio Announces 2026 Annual Meeting of StockholdersJuly 13 at 10:15 PM | globenewswire.comTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10, 2026 | finanznachrichten.deTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO AcquisitionsJune 9, 2026 | quiverquant.comQTevogen Announces Formation of a Healthcare Services InitiativeJune 9, 2026 | globenewswire.comTevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | finanznachrichten.deSee More Tevogen Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email. Email Address About Tevogen BioTevogen Bio (NASDAQ:TVGN) plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML). In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections. Its research and development efforts seek to harness both non-engineered and engineered NK cells, including chimeric antigen receptor (CAR) NK constructs, to address a broad range of diseases. The company’s technology platform is protected by patents covering manufacturing processes and product compositions. Founded in 2013 by a team of immunotherapy experts, Tevogen Bio maintains research facilities in the United States, Israel and Denmark. Under the leadership of co-founder and Chief Executive Officer Khurshid Guru, the company has progressed from early-stage discovery to clinical development. It is actively expanding its manufacturing capabilities to support late-stage trials and future commercialization efforts. Tevogen Bio collaborates with academic institutions and drug development partners to accelerate its pipeline. The company engages with regulatory authorities in North America and Europe as it advances clinical programs and prepares for potential market entry. By focusing on the innate immune system and personalized therapeutic approaches, Tevogen Bio aims to address unmet medical needs in oncology and viral disease treatment.View Tevogen Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-MergerMarriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Upcoming Earnings Fifth Third Bancorp (7/17/2026)Truist Financial (7/17/2026)Travelers Companies (7/17/2026)HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
